Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab

Due to the risk of rapidly progressive osteoarthritis (RPOA), the phase III studies of subcutaneous (SC) tanezumab in patients with moderate to severe hip or knee osteoarthritis (OA) included comprehensive joint safety surveillance. This pooled analysis summarizes these findings.

Source: Osteoarthritis and Cartilage - August 29, 2023 Category: Rheumatology Authors: John A. Carrino, Timothy E McAlindon, Tom J. Schnitzer, Ali Guermazi, Marc C. Hochberg, Philip G. Conaghan, Mark T. Brown, Aimee Burr, Robert J. Fountaine, Glenn C. Pixton, Lars Viktrup, Kenneth M. Verburg, Christine West Source Type: research